Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
Rhea-AI Summary
Optimi Health (NASDAQ: OPTH) highlighted updated Therapeutic Goods Administration recommendations for Australia's Authorized Prescriber framework covering prescribed psilocybin and MDMA.
The changes broaden therapist eligibility, permit treatment in more medically supervised settings, confirm no serious adverse events since December 2025, and extend reimbursement across public and private payers.
AI-generated analysis. Not financial advice.
Positive
- Broader therapist eligibility under Australia’s updated Authorized Prescriber framework
- Psychedelic-assisted therapy allowed in medically supervised non-hospital environments
- Aggregated data show no serious adverse events reported since December 2025
- Expanded reimbursement from both public schemes and private insurer Medibank
- Growing training ecosystem with more than 750 clinicians holding CPAT certification
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
No peers from the Healthcare / Drug Manufacturers - Specialty & Generic group appeared in the momentum scan, suggesting this move was stock-specific rather than part of a broader sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 26 | Product advancement | Positive | -2.4% | Highest-purity natural psilocybin extract to support Australian and European programs. |
| May 21 | Equity offering | Negative | -6.3% | Oversubscribed US$15M public offering and Nasdaq uplisting at US$6.25 per share. |
Recent operational progress drew negative price reactions, while a dilutive financing aligned with a price drop, indicating some selling into both good news and offerings.
In the last week, Optimi reported two notable events. On May 26, 2026, it announced completion of its highest-purity natural psilocybin extract (about 6% psilocybin) aimed at Australian TRD prescriptions and European research; shares fell 2.39%. Earlier, on May 21, 2026, the company closed an oversubscribed US$15 million public offering tied to its Nasdaq uplisting, with a 6.25% decline, highlighting sensitivity to dilution and profit-taking around milestones.
Market Pulse Summary
This announcement highlighted expanded access to psychedelic-assisted therapy in Australia, including broader therapist eligibility, non-hospital treatment settings, and reimbursement from both public and private payers. A clean real-world safety profile with 0 serious adverse events under the AP scheme and training of more than 750 clinicians underpin the program’s credibility. Investors may track prescription volumes, additional safety data, and further policy adjustments as key indicators for Optimi’s commercial opportunity.
Key Terms
psilocybin medical
mdma medical
post-traumatic stress disorder medical
treatment-resistant depression medical
gmp-compliant technical
psychedelic-assisted psychotherapy medical
schedule 8 regulatory
human research ethics committee regulatory
AI-generated analysis. Not financial advice.
Updated TGA recommendations broaden therapist eligibility, accept a wider range of treatment settings, and reinforce Australia's position as the world's leading commercial market for prescribed psilocybin and MDMA
VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- via IBN – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage psychedelic pharmaceutical manufacturer, today acknowledged the final recommendations published by the Therapeutic Goods Administration ("TGA") following its targeted consultation on the Authorized Prescriber ("AP") scheme for psilocybin and MDMA.
Under the AP scheme, authorized psychiatrists may prescribe Optimi's MDMA for the treatment of post-traumatic stress disorder ("PTSD") and psilocybin for treatment-resistant depression ("TRD") from the Company's GMP-compliant production facility in Canada, making Australia the first country in the world to recognize, and regulate, both substances as medicines for these indications.
The updated framework, published following stakeholder consultation that closed on May 19, 2026, introduces material changes to how psychedelic-assisted psychotherapy ("PAT") is delivered in Australia. The changes are designed to expand the eligible workforce, open new categories of treatment setting, and accelerate scaling of Australia's commercial program, which remains the leading reference point globally for prescribed psilocybin and MDMA care.
"The TGA's updated framework is a meaningful step toward unlocking the workforce, settings, and prescriber base needed to further scale psychedelic-assisted therapy in Australia," said Dane Stevens, CEO of Optimi. "After over two years of regulated commercial use, no serious adverse events have been reported under the scheme. Australia continues to be the most advanced commercial reference point for what reimbursed, real-world psychedelic care looks like, and Optimi is positioned to support that expansion as patient volumes increase."
Therapy Team Composition Has Been Broadened
Under the updated framework, the therapy dyad must include at least one therapist registered with a National Board and the AP psychiatrist is required to be physically present on-site during administration of the medicine and to conduct real-time patient screening and informed consent.
The second practitioner in the dosing room may be drawn from the wider pool of suitably trained professionals, including psychotherapists, counsellors, social workers, and Aboriginal and Torres Strait Islander health workers. The AP psychiatrist is responsible for determining qualifications and competency of any additional practitioner, subject to oversight by the relevant Human Research Ethics Committee (“HREC").
Australia's training ecosystem supports the Certificate in Psychedelic-Assisted Therapy ("CPAT(TM)"), delivered by Mind Medicine Australia, which has trained more than 750 clinicians. The program is accredited under Australian Medical CPD Standards, recognized by HRECs and the TGA, and offers 127+ CPD hours, clinical experience pathways, and a national alumni network.
This change opens the door to genuinely multidisciplinary therapy teams. The TGA noted that the broader composition will support workforce capacity in rural and regional Australia, address shortages, and improve culturally appropriate care.
Treatment Can Now Occur Outside Hospital Settings
The TGA has confirmed that PAT can be delivered in any medically supervised environment that meets defined safety standards. Sites must provide secure Schedule 8 storage, trained staff and equipment for clinical care and resuscitation, immediate access to rescue medications, robust documentation, and a location within 15 minutes of an accredited healthcare facility with an emergency department.
This represents a meaningful shift from prior assumptions that day hospital or inpatient settings were required, and aligns with stakeholder feedback that less clinical, more therapeutic environments often improve patient comfort and outcomes.
Real-World Safety Profile Remains Clean
Aggregated data obtained from the TGA confirm that no serious adverse events have been reported under the AP scheme since December 2025. Every AP psychiatrist is required to report patient numbers and any serious adverse events to the relevant Human Research Ethics Committee, the TGA, and the applicable state health department, providing a structured real-world safety surveillance framework. Adverse event and outcome data are also being collected by the Australian Interventional Pharmacotherapy and Psychedelic Assisted Psychotherapy Research Registry ("AIPPAP-RR") hosted by the Australian National University.
This clean safety profile, accumulated under regulated commercial conditions rather than a clinical trial environment, supports the case for continued program expansion.
Reimbursement Now Spans Public and Private Payers
Coverage for psychedelic-assisted therapy in Australia is no longer confined to private pay and now spans both sides of the funding system. Public coverage includes the Department of Veterans' Affairs ("DVA"), the National Disability Insurance Scheme ("NDIS"), and WorkCover schemes. Private coverage includes Medibank, Australia's largest private health insurer. The combination of an expanded prescriber and therapist workforce, broader site eligibility, and growing reimbursement across public and private payers creates a credible employment pathway for trained practitioners and an addressable patient population for commercial supply.
About Optimi Health Corp.
Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada.
Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.
For more information, please visit www.optimihealth.ca or optimi.net
For more information, please contact:
Dane Stevens, CEO
Optimi Health Corp.
(778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
(262) 357-2918
OPTHF@mzgroup.us
www.mzgroup.us
Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, including statements regarding the expected impact of the Therapeutic Goods Administration's updated Authorised Prescriber framework, including expanded therapist eligibility, broader treatment setting eligibility, increasing reimbursement availability, Australia's continued development as a commercial market for prescribed psilocybin and MDMA therapies, the safety and scalability of the Authorised Prescriber program, and the Company's ability to support growth in patient access and commercial demand in Australia and other international markets. Forward-looking statements are often identified by words such as "expects," "anticipates," "believes," "intends," "plans," "may," "will," "would," "could," or similar expressions. Forward-looking statements are based on several assumptions and are subject to a number of known and unknown risks and uncertainties, many of which are beyond the Company's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include those described under "Risk Factors" in the Company's registration statement on Form F-1, as amended, and other filings with the U.S. Securities and Exchange Commission made from time to time which are available at www.sec.gov or in the Company's continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.ca. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement.
Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.
InvestorWire Service Contact:
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
